4.6 Review

Fibroblast growth factors, old kids on the new block

Journal

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
Volume 53, Issue -, Pages 155-167

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcdb.2015.12.014

Keywords

Fibroblast growth factor; Receptor tyrosine kinase; Heparan sulfate; Klotho; Clinical application of FGF

Funding

  1. National Institutes of Health [CA96824, DE023106, CA140388]
  2. Cancer Prevention and Research Institution of Texas [CPRIT110555, TAMU1400302]
  3. Natural Science Foundation of Zhejiang Province of China [Y2110492]
  4. National Natural Science Foundation of China [81101712, 31371470, 81270761]

Ask authors/readers for more resources

The fibroblast growth factors (FGFs) are a family of cell intrinsic regulatory peptides that control a broad spectrum of cellular activities. The family includes canonic FGFs that elicit their activities by activating the FGF receptor (FGFR) tyrosine kinase and non-canonic members that elicit their activities intracellularly and via FGFR-independent mechanisms. The FGF signaling axis is highly complex due to the existence of multiple isoforms of both ligands and receptors, as well as cofactors that include the chemically heterogeneous heparan sulfate (HS) cofactors, and in the case of endocrine FGFs, the Klotho coreceptors. Resident FGF signaling controls embryonic development, maintains tissue homeostasis, promotes wound healing and tissue regeneration, and regulates functions of multiple organs. However, ectopic or aberrant FGF signaling is a culprit for various diseases, including congenital birth defects, metabolic disorder, and cancer. The molecular mechanisms by which the specificity of FGF signaling is achieved remain incompletely understood. Since its application as a druggable target has been gradually recognized by pharmaceutical companies and translational researchers, understanding the determinants of FGF signaling specificity has become even more important in order to get into the position to selectively suppress a particular pathway without affecting others to minimize side effects. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available